Skip to main content
Signal8
Launch Terminal
Huizenga Theodore Alan profile photo

Theodore Alan Huizenga

CIK: 0001603347

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (57.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (21.4%)

Compensation grants

Other (G, F, J, C, D, …)3 (21.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Ultragenyx Pharmaceutical Inc. logo
RARE

Ultragenyx Pharmaceutical Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Sep 15, 2026
    Sale(S)
    Direct
    1.3K shares at avg. $13.57$17K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Sep 3, 2026
    Sale(S)
    Direct
    161 shares at avg. $13.99$2K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Apr 22, 2026
    Award(A)
    Direct
    20.2K shares-
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Mar 2, 2026
    Tax Payment(F)
    Direct
    148 shares at avg. $23.39$3K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Mar 2, 2026
    Sale(S)
    Direct
    1.6K shares at avg. $22.80$37K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Dec 29, 2025
    Sale(S)
    Direct
    85 shares at avg. $34.38$3K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Sep 18, 2025
    Sale(S)
    Direct
    64 shares at avg. $29.17$2K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Sep 5, 2025
    Sale(S)
    Direct
    84 shares at avg. $31.39$3K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Mar 3, 2025
    Sale(S)
    Direct
    967 shares at avg. $42.10$41K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Mar 3, 2025
    Tax Payment(F)
    Direct
    141 shares at avg. $42.92$6K
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Mar 1, 2025
    Award(A)
    Direct
    9.4K shares-
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Dec 10, 2024
    Gift(G)
    Direct
    648 shares-
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Sep 16, 2024
    Award(A)
    Direct
    700 shares-
  • Ultragenyx Pharmaceutical Inc. logo
    RARE

    Ultragenyx Pharmaceutical Inc.

    Sep 3, 2024
    Sale(S)
    Direct
    91 shares at avg. $56.19$5K

1-14 of 14

About Huizenga Theodore Alan

Huizenga Theodore Alan (SEC CIK 0001603347) files insider reports with the SEC as SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc. (RARE).

Signal8 holds 11 ownership filings by Huizenga Theodore Alan, all Form 4s, filed between Sep 5, 2024 and Sep 15, 2026. Those filings report 14 transactions, from Sep 3, 2024 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Huizenga Theodore Alan's filings is in NOVATO, CA.

Recent filings by Huizenga Theodore Alan

  • Sep 15, 2026: Open-market sale of RARE shares (Form 4, code S).
  • Sep 3, 2026: Open-market sale of RARE shares (Form 4, code S).
  • Apr 22, 2026: Grant or award of RARE shares (Form 4, code A).
  • Mar 2, 2026: Tax withholding of RARE shares (Form 4, code F).
  • Mar 2, 2026: Open-market sale of RARE shares (Form 4, code S).

Other insiders filing for Ultragenyx Pharmaceutical Inc. (RARE)

How to read Form 4 transaction codes